Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Robert Green, Shashikant Kulkarni, Rong Chen, Mark Gerstein, and more


Bina Technologies has added four new members to its advisory board. They are Robert Green, an associate professor of medicine at Brigham and Women’s Hospital and Harvard Medical School, and associate director for research at the Partners HealthCare Center for Personalized Genetic Medicine; Shashikant Kulkarni, the director of cytogenomics and molecular pathology, and an associate professor of pathology and immunology, pediatrics, and genetics at Washington University School of Medicine; Rong Chen, the director of clinical genome informatics at the Icahn Institute of Genetics and Multiscale Biology; and Mark Gerstein, a Yale University professor of biomedical informatics, molecular biophysics & biochemistry, and computer Science.

Bina has also added two new members to its executive team. Janet Lankard has been hired as vice president of sales, and Gianfranco de Feo is now the company's vice president of marketing.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.